Greenwich LifeSciences (GLSI) and Its Rivals Head to Head Contrast

Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) is one of 967 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Greenwich LifeSciences to similar companies based on the strength of its valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Profitability

This table compares Greenwich LifeSciences and its peers’ net margins, return on equity and return on assets.

 Net MarginsReturn on EquityReturn on Assets
Greenwich LifeSciencesN/A-37.58%-37.06%
Greenwich LifeSciences Competitors-3,194.93%-184.70%-33.34%

Institutional and Insider Ownership

8.1% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 42.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 52.1% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Greenwich LifeSciences and its peers revenue, earnings per share and valuation.

 Gross RevenueNet IncomePrice/Earnings Ratio
Greenwich LifeSciencesN/A-$4.57 million-19.00
Greenwich LifeSciences Competitors$1.81 billion$243.57 million-5.78

Greenwich LifeSciences’ peers have higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Greenwich LifeSciences has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences’ peers have a beta of 0.95, suggesting that their average stock price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Greenwich LifeSciences and its peers, as provided by MarketBeat.

 Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Greenwich LifeSciences00103.00
Greenwich LifeSciences Competitors341613574397256632.66

Greenwich LifeSciences presently has a consensus price target of $78.00, suggesting a potential upside of 620.22%. As a group, “Pharmaceutical preparations” companies have a potential upside of 97.81%. Given Greenwich LifeSciences’ stronger consensus rating and higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than its peers

(Visited 1 times, 1 visits today)

Leave A Comment

Your email address will not be published. Required fields are marked *